[go: up one dir, main page]

DE69606028D1 - Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung - Google Patents

Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung

Info

Publication number
DE69606028D1
DE69606028D1 DE69606028T DE69606028T DE69606028D1 DE 69606028 D1 DE69606028 D1 DE 69606028D1 DE 69606028 T DE69606028 T DE 69606028T DE 69606028 T DE69606028 T DE 69606028T DE 69606028 D1 DE69606028 D1 DE 69606028D1
Authority
DE
Germany
Prior art keywords
taxal
derivatives
production
pharmaceutical composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69606028T
Other languages
English (en)
Other versions
DE69606028T2 (de
Inventor
Herve Bouchard
Jean-Dominique Bourzat
Alain Commercon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9503545A external-priority patent/FR2732340B1/fr
Priority claimed from FR9515381A external-priority patent/FR2742754B1/fr
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of DE69606028D1 publication Critical patent/DE69606028D1/de
Publication of DE69606028T2 publication Critical patent/DE69606028T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69606028T 1995-03-27 1996-03-25 Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung Expired - Lifetime DE69606028T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9503545A FR2732340B1 (fr) 1995-03-27 1995-03-27 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR9515381A FR2742754B1 (fr) 1995-12-22 1995-12-22 Procede de preparation de taxoides
PCT/FR1996/000440 WO1996030355A1 (fr) 1995-03-27 1996-03-25 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
DE69606028D1 true DE69606028D1 (de) 2000-02-10
DE69606028T2 DE69606028T2 (de) 2000-08-10

Family

ID=26231838

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69604653T Expired - Lifetime DE69604653T2 (de) 1995-03-27 1996-03-25 Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen
DE69606028T Expired - Lifetime DE69606028T2 (de) 1995-03-27 1996-03-25 Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69604653T Expired - Lifetime DE69604653T2 (de) 1995-03-27 1996-03-25 Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen

Country Status (41)

Country Link
US (3) US5889043A (de)
EP (2) EP0817780B1 (de)
JP (2) JP2941951B2 (de)
KR (2) KR100297196B1 (de)
CN (2) CN1152870C (de)
AP (2) AP785A (de)
AR (1) AR001440A1 (de)
AT (2) ATE185562T1 (de)
AU (2) AU703278B2 (de)
BG (2) BG63009B1 (de)
BR (2) BR9607930A (de)
CA (2) CA2214321C (de)
CO (1) CO4700576A1 (de)
CZ (2) CZ287326B6 (de)
DE (2) DE69604653T2 (de)
DK (2) DK0817779T3 (de)
DZ (1) DZ2009A1 (de)
EA (2) EA000709B1 (de)
EE (2) EE03608B1 (de)
ES (2) ES2140075T3 (de)
GE (2) GEP20002211B (de)
GR (2) GR3031526T3 (de)
HU (2) HU223732B1 (de)
IL (1) IL117636A (de)
IS (2) IS2058B (de)
MA (1) MA23823A1 (de)
MY (1) MY121225A (de)
NO (2) NO316379B1 (de)
NZ (2) NZ304901A (de)
OA (2) OA10514A (de)
PE (1) PE51097A1 (de)
PL (2) PL188284B1 (de)
PT (1) PT817779E (de)
RO (2) RO115878B1 (de)
SK (2) SK281927B6 (de)
TN (1) TNSN96043A1 (de)
TR (2) TR199701042T1 (de)
TW (1) TW394765B (de)
UY (2) UY24192A1 (de)
WO (2) WO1996030356A1 (de)
ZA (1) ZA962399B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500858B2 (en) 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5811452A (en) * 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US7288665B1 (en) * 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
FR2771092B1 (fr) * 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
EP0982027A1 (de) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid-Derivaten zur Behandlung von abnormaler Zellvermehrung des Gehirns
HUP0104000A3 (en) * 1998-08-20 2003-01-28 Aventis Pharma Sa New use of taxoid derivatives
EP0982028A1 (de) * 1998-08-20 2000-03-01 Aventis Pharma S.A. Neue Verwendung von Taxoidverbindungen
EP1020188A1 (de) * 1999-01-13 2000-07-19 Aventis Pharma S.A. Neue Verwendung von Taxoid-Derivaten
US6649632B2 (en) * 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
PL350027A1 (en) 2000-02-02 2002-10-21 Univ Florida State Res Found C10 heterosubstituted acetate taxanes as antitumor agents
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
CZ2003837A3 (cs) 2000-09-22 2004-12-15 Bristol-Myers Squibb Company Způsob pro snížení toxicity při kombinovaných chemoterapiích
WO2002024178A2 (en) * 2000-09-22 2002-03-28 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US6593334B1 (en) 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
PT1534340E (pt) 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
AU2003291458A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
AU2003239511A1 (en) * 2003-05-20 2004-12-13 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
US7064980B2 (en) * 2003-09-17 2006-06-20 Sandisk Corporation Non-volatile memory and method with bit line coupled compensation
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GT200500025A (es) * 2004-02-13 2005-09-30 Taxanos sustituidos con esteres de ciclopentilo en c10
PE20050693A1 (es) * 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
US20060189679A1 (en) * 2005-02-14 2006-08-24 Florida State University Research Foundation, Inc. C10 cyclopropyl ester substituted taxane compositions
PL1871753T3 (pl) 2005-03-31 2012-12-31 Accord Healthcare Inc Wytwarzanie taksanów z 9-dihydro-13-acetylobakatyny iii
ES2435724T3 (es) * 2005-11-04 2013-12-23 Accord Healthcare Inc. Nuevos métodos para la preparación de taxanos usando auxiliares quirales
US7847111B2 (en) * 2006-06-19 2010-12-07 Canada Inc. Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20100197944A1 (en) * 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US8242166B2 (en) 2008-03-31 2012-08-14 Florida State University Research Foundation, Inc. C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
SG10201810928SA (en) 2009-10-29 2019-01-30 Aventis Pharma Sa Novel antitumoral use of cabazitaxel
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US8791279B2 (en) * 2010-12-13 2014-07-29 Yung Shin Pharm. Ind. Co., Ltd. Process for preparing taxoids from baccatin derivatives using lewis acid catalyst
US20130338216A1 (en) 2010-12-22 2013-12-19 Nektar Therapeutics Deuterated and/or fluorinated taxane derivatives
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN102060815B (zh) * 2010-12-24 2012-09-26 重庆泰濠制药有限公司 一种紫杉烷类化合物的制备方法
TWI598097B (zh) 2011-02-25 2017-09-11 安萬特醫藥公司 包含卡巴利他索(cabazitaxel)及順鉑(cisplatin)之抗腫瘤組合
EP2620148A1 (de) 2012-01-27 2013-07-31 Aventis Pharma S.A. Antitumorkombination mit Cabazitaxel und Cisplatin
EP2491925A1 (de) 2011-02-25 2012-08-29 Aventis Pharma S.A. Antitumorigene Kombinaton, die Cabazitaxel und Cisplatin umfasst
CN103764637A (zh) 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
PH12014500106A1 (en) 2011-08-02 2019-03-22 Astellas Pharma Inc Method for treating cancer by combined use of drugs
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
CN104039771B (zh) * 2011-09-26 2017-10-27 Kabi费森尤斯肿瘤学有限公司 包括c(7)‑oh和c(13)‑oh甲硅烷基化或仅c(7)‑oh甲硅烷基化的用于制备卡巴他赛的方法
CN102336726B (zh) * 2011-09-30 2014-11-26 重庆泰濠制药有限公司 一种卡巴他赛的制备方法
US20130090484A1 (en) * 2011-10-11 2013-04-11 Scinopharm Taiwan Ltd. Process for making an intermediate of cabazitaxel
CN102408397B (zh) 2011-10-19 2014-08-20 上海贝美医药科技有限公司 紫杉烷类衍生物及其制备方法
CN102516281B (zh) * 2011-10-20 2015-02-04 江苏红豆杉生物科技股份有限公司 一种10-脱乙酰基巴卡丁iii及其衍生物甲氧基化的方法
CN102424672A (zh) * 2011-10-20 2012-04-25 江苏红豆杉生物科技有限公司 脱保护基制备二甲氧基紫杉烷类化合物的方法
CN102603724B (zh) * 2011-10-20 2014-02-26 江苏红豆杉生物科技股份有限公司 二甲氧基紫杉烷类化合物纯化精制的方法
WO2013072766A2 (en) * 2011-10-31 2013-05-23 Scinopharm Taiwan, Ltd. Process for cabazitaxel and intermediates thereof
CN102417491B (zh) * 2011-10-31 2013-11-06 江苏红豆杉生物科技有限公司 以10-去乙酰基-巴卡丁iii为原料制备卡巴他赛的方法
CN103874692A (zh) * 2011-11-01 2014-06-18 费森尤斯卡比肿瘤学有限公司 卡巴他赛的无定形形式和用于其制备的方法
CN103159705B (zh) * 2011-12-12 2015-05-27 福建南方制药股份有限公司 卡巴他赛中间体的制备方法
EP2791122B1 (de) 2011-12-13 2019-01-23 Aventis Pharma S.A. Kristalline form von cabazitaxel und herstellungsverfahren dafür
CN102532064B (zh) * 2011-12-13 2015-06-17 重庆泰濠制药有限公司 二甲氧基多西他赛的合成方法
CN104583189A (zh) * 2012-07-31 2015-04-29 永信药品工业股份有限公司 非晶型的卡巴利他索
CN102775435B (zh) * 2012-08-21 2015-04-08 江苏红豆杉生物科技股份有限公司 一种用于制备7,10-甲氧基多西他赛的中间体的合成方法
CN102775434B (zh) * 2012-08-21 2015-04-08 江苏红豆杉生物科技股份有限公司 一种7,10-二甲氧基紫杉烷化合物中间体的合成方法
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
KR101407353B1 (ko) 2012-12-04 2014-06-17 주식회사 삼양바이오팜 10-디아세틸바카틴 iii으로부터 카바지탁셀을 고수율로 제조하는 새로운 방법 및 이를 위한 신규 중간체
EP2743264A1 (de) 2012-12-13 2014-06-18 INDENA S.p.A. Neue kristalline Form von Cabazitaxel, Verfahren zur Herstellung und pharmazeutische Zusammensetzungen davon
EP2815749A1 (de) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
EP2865675A1 (de) 2013-10-23 2015-04-29 INDENA S.p.A. Kristalline wasserfreie Form von Cabazitaxel, Herstellungsverfahren dafür und pharmazeutische Zusammensetzungen damit
EP2865674A1 (de) 2013-10-23 2015-04-29 INDENA S.p.A. Kristalline Solvatformen von Cabazitaxel
CN104650012A (zh) * 2013-11-22 2015-05-27 天士力控股集团有限公司 一种紫杉烷类化合物
CN104086514A (zh) * 2014-06-19 2014-10-08 上海应用技术学院 紫杉醇衍生物及其制备方法
PL3258931T3 (pl) 2015-02-17 2020-12-28 Erasmus University Medical Center Rotterdam Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
EP3093014A1 (de) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel und dessen verwendung zur behandlung von krebs
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
CN114080225A (zh) 2019-08-08 2022-02-22 来凯有限公司 治疗癌症的方法
EP3797834A1 (de) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrc-patienten, die zuvor mit docetaxel behandelt wurden und bei denen ein vorheriger, auf androgensignalisierung abzielender inhibitor versagt hat
EP3808345A1 (de) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel bei mcrc-patienten, die zuvor mit docetaxel behandelt wurden und bei denen ein vorheriger, auf androgensignalisierung abzielender inhibitor versagt hat

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2629819B1 (fr) 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5739362A (en) 1991-09-23 1998-04-14 Florida State University Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5489601A (en) 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5319112A (en) 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
FR2696459B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
MX9308012A (es) 1992-12-24 1994-08-31 Bristol Myers Squibb Co Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
TW467896B (en) 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
CA2129288C (en) * 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
CA2179490A1 (en) 1993-12-21 1995-06-29 Trimurtulu Golakoti New cryptophycins
ES2123996T3 (es) 1994-06-28 1999-01-16 Upjohn Co Analogos de 7-etertaxol, uso antineoplasico y composiciones farmaceuticas que los contienen.
US6201140B1 (en) 1994-07-28 2001-03-13 Bristol-Myers Squibb Company 7-0-ethers of taxane derivatives
US5481018A (en) 1995-03-31 1996-01-02 The Dow Chemical Company Amino nitrile intermediate for the preparation of alanine diacetic acid
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides

Also Published As

Publication number Publication date
SK281927B6 (sk) 2001-09-11
CN1179776A (zh) 1998-04-22
AU5278096A (en) 1996-10-16
EE9700323A (et) 1998-06-15
DK0817779T3 (da) 2000-06-19
MA23823A1 (fr) 1996-10-01
BR9607930A (pt) 1998-06-02
HUP9801204A3 (en) 2000-12-28
NO973923L (no) 1997-08-26
ES2143187T3 (es) 2000-05-01
EA199700269A1 (ru) 1998-04-30
US5889043A (en) 1999-03-30
WO1996030355A1 (fr) 1996-10-03
HUP9801201A2 (hu) 2000-05-28
NZ304900A (en) 1998-09-24
EE9700315A (et) 1998-06-15
JPH11502531A (ja) 1999-03-02
OA10514A (fr) 2002-04-22
OA10513A (fr) 2002-04-22
JPH11500141A (ja) 1999-01-06
NO973923D0 (no) 1997-08-26
NO973922L (no) 1997-08-26
TNSN96043A1 (fr) 2005-03-15
CN1152870C (zh) 2004-06-09
TW394765B (en) 2000-06-21
CZ287468B6 (en) 2000-12-13
EP0817780B1 (de) 1999-10-13
DK0817780T3 (da) 2000-03-27
PE51097A1 (es) 1997-12-22
IL117636A0 (en) 1996-07-23
AU711227B2 (en) 1999-10-07
UY24370A1 (es) 2001-10-25
GEP20002211B (en) 2000-08-25
NO973922D0 (no) 1997-08-26
DE69604653D1 (de) 1999-11-18
RO115878B1 (ro) 2000-07-28
EE03608B1 (et) 2002-02-15
KR19980703357A (ko) 1998-10-15
NO316379B1 (no) 2004-01-19
PL188987B1 (pl) 2005-05-31
CA2214321C (fr) 2008-01-22
KR100297196B1 (ko) 2001-11-22
MY121225A (en) 2006-01-28
CN1179775A (zh) 1998-04-22
GEP20002188B (en) 2000-07-25
PL322499A1 (en) 1998-02-02
PT817779E (pt) 2000-04-28
AP9701093A0 (en) 1997-10-31
AU5278196A (en) 1996-10-16
TR199701040T1 (xx) 1998-01-21
TR199701042T1 (xx) 1998-01-21
BG101917A (en) 1998-10-30
AP9701090A0 (en) 1997-10-31
JP2941951B2 (ja) 1999-08-30
ZA962399B (en) 1996-10-01
SK130297A3 (en) 1998-03-04
AR001440A1 (es) 1997-10-22
BG63009B1 (bg) 2001-01-31
PL188284B1 (pl) 2005-01-31
AU703278B2 (en) 1999-03-25
BR9607929A (pt) 1998-06-02
BG63121B1 (bg) 2001-04-30
JP3790826B2 (ja) 2006-06-28
NZ304901A (en) 1998-12-23
HU223732B1 (hu) 2004-12-28
US6387946B1 (en) 2002-05-14
MX9706568A (es) 1997-11-29
MX9706278A (es) 1997-10-31
IS2058B (is) 2005-10-14
CA2214321A1 (fr) 1996-10-03
AP753A (en) 1999-07-21
DE69604653T2 (de) 2000-05-31
RO115877B1 (ro) 2000-07-28
ATE188471T1 (de) 2000-01-15
SK281928B6 (sk) 2001-09-11
CA2214319C (fr) 2004-02-17
CZ287326B6 (en) 2000-10-11
SK130197A3 (en) 1998-04-08
EP0817779A1 (de) 1998-01-14
IL117636A (en) 2004-08-31
ES2140075T3 (es) 2000-02-16
CZ303297A3 (cs) 1998-01-14
UY24192A1 (es) 1996-06-14
IS4536A (is) 1997-07-31
HU223666B1 (hu) 2004-11-29
PL322465A1 (en) 1998-02-02
KR100485309B1 (ko) 2005-10-12
GR3031526T3 (en) 2000-01-31
CN1213042C (zh) 2005-08-03
EE03609B1 (et) 2002-02-15
NO316607B1 (no) 2004-03-08
EP0817780A1 (de) 1998-01-14
KR19980703287A (ko) 1998-10-15
BG101918A (en) 1998-10-30
CA2214319A1 (fr) 1996-10-03
DZ2009A1 (fr) 2002-10-23
EA000567B1 (ru) 1999-12-29
AP785A (en) 1999-11-26
WO1996030356A1 (fr) 1996-10-03
DE69606028T2 (de) 2000-08-10
ATE185562T1 (de) 1999-10-15
IS4567A (is) 1997-09-23
GR3032316T3 (en) 2000-04-27
HUP9801201A3 (en) 2000-12-28
CO4700576A1 (es) 1998-12-29
EA000709B1 (ru) 2000-02-28
CZ303097A3 (cs) 1998-01-14
EP0817779B1 (de) 2000-01-05
IS2056B (is) 2005-10-14
EA199700270A1 (ru) 1998-02-26
US20020038038A1 (en) 2002-03-28
HUP9801204A1 (hu) 2000-05-28
US6331635B1 (en) 2001-12-18

Similar Documents

Publication Publication Date Title
ATE188471T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung
DE69630145D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
ATE239703T1 (de) Azetidinderivate, deren herstellung und sie enthaltende arzneimittel
DE69806831D1 (de) Dithiolan Derivate, deren Herstellung und deren Heileffekt
ATE187167T1 (de) Amido-3-pyrazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69928260D1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
ATE164843T1 (de) Naphthalinderivate, ihre herstellungsverfahren und zwischenprodukte dafür, und diese enthaltende pharmazeutische zusammensetzungen
DE59907961D1 (de) Indeno-, naphtho- und benzocyclohepta-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
DE69915693D1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
EE9700020A (et) Heteroaatomit sisaldavad tsülopentaanpüridüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
EE9700044A (et) Heteroarüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid.
ATE193533T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE297935T1 (de) 2-(iminomethyl)aminophenyl-derivate, deren herstellung, verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
DE69815094D1 (de) 2-(iminoethyl)-aminophenyl - derivate, deren herstellung, deren verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
DE69715009D1 (de) Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten
DE50003761D1 (de) Indeno-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
DE69706146D1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69610085D1 (de) Taxol derivate,deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69204909D1 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
DE69520870D1 (de) Esculetin Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellung
DE3578597D1 (de) 4-phenylphthalazin-derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE60012750D1 (de) Neue xanthon derivate, deren herstellung und verwendung als arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC